Molbio Diagnostics IPO Subscription Reaches 1.22 Times, Employee Portion Leads Demand On Day 2
Mumbai: Molbio Diagnostics’ initial public offering (IPO) was subscribed 1.22 times by the end of Day 2 on Tuesday, August 11, 2026. The Rs 939.70-crore public issue opened on August 10 and will close on August 12. Demand Across Categories The employee portion received the strongest response and was subscribed 2.69 times on Day 2, compared with 2.12 times on the opening day. The non-institutional…
Mumbai: The subscription rate for Molbio Diagnostics' IPO reached 1.22 times by the close of Day 2 on Tuesday, August 11, 2026. The public offering, which opened on August 10, will conclude on August 12, with a target of Rs 939.70 crore. Employee Shares Draw Strongest Demand The employee shares garnered the most interest, subscribing 2.69 times on Day 2, up from 2.12 times on the opening day.
Non-Institutional Investors Show Growth The non-institutional investor (NII) category saw a rise from 0.73 times on Day 1 to 1.37 times on Day 2. Within this group, the small NII portion was subscribed 1.67 times, while the larger portion attracted 1.22 times bids. Retail Investor Participation Increases Retail investors also showed increased interest, subscribing 1.26 times to the retail individual investor portion, compared to 0.77 times on the first day.
Institutional Investors Unchanged The qualified institutional buyer (QIB) category maintained its subscription rate at 1.00 time, unchanged from Day 1. Overall Subscription Improvement Subscription improved from 0.83 times on Monday to 1.22 times on Tuesday. Pricing and Lot Size The IPO has a price band of Rs 768 to Rs 807 per equity share.
Investors may apply for a minimum lot of 18 shares. At the upper end of the price range, one lot will cost Rs 14,526. Allocation of Offer The total offer is divided as 50 percent for QIBs, 35 percent for retail investors, and 15 percent for non-institutional investors. Shares are slated to be listed on both the BSE and NSE. Molbio Diagnostics Aims for IPO Price Band of ₹768-807; Issue Begins on August 10 Company Background Molbio Diagnostics creates rapid and affordable testing solutions for infectious and non-communicable diseases.
Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Ideal for point-of-care testing, including in locations with limited laboratory resources, the platform is manufactured by the company's wholly owned subsidiary, Bigtec Labs. Molbio Diagnostics Files IPO With SEBI, Seeks Funds for Expansion How to Apply Investors can apply through the ASBA facility provided by banks or via supported stockbroking applications using UPI.
Before making any investment decision, applicants should review the price, business risks, financial performance, and subscription data.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
